Payment overview · 2025
General Payments
$317.07
19 reported records · 3 companies
Healthcare provider profile · identity verified
Denise Gomez, M.D
Allopathic & Osteopathic Physicians|General Practice · OCEANSIDE, CA · NPI 1407871817
Verified facts
What the public records show
CMS Open Payments records show Denise Gomez, M.D received $317.07 in general payments during 2025 across 19 reported records.
Gilead Sciences, Inc. accounted for 69.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Biktarvy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $221.16 | 69.8% | 15 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $79.05 | 24.9% | 3 | 2025 |
| BSN Medical Inc | Unresolved — no canonical attribution shown | $16.86 | 5.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $317.07 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $117.09 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $50.00 | 1 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $23.63 | 4 | 2025 |
Source payment records
|
|||||
| JOBST SPORT Normalized: jobst sport |
Device | BSN Medical Inc | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $14.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 602 | 135 |
| Amlodipine Besylate | Amlodipine Besylate | 315 | 80 |
| Metformin Hcl | Metformin Hcl | 294 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 247 | 54 |
| Lisinopril | Lisinopril | 234 | 53 |
| Gabapentin | Gabapentin | 201 | 41 |
| Losartan Potassium | Losartan Potassium | 194 | 49 |
| Jardiance | Empagliflozin | 183 | 41 |
| Omeprazole | Omeprazole | 156 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 124 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 113 | 36 |
| Meloxicam | Meloxicam | 107 | 29 |
| Alendronate Sodium | Alendronate Sodium | 105 | 27 |
| Carvedilol | Carvedilol | 95 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 95 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 93 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 19 |
| Furosemide | Furosemide | 85 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 76 | 20 |
| Ozempic | Semaglutide | 75 | 14 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 64 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 60 | 15 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 58 | 11 |
| Metformin Hcl Er | Metformin Hcl | 58 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 57 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 56 | 13 |
| Tradjenta | Linagliptin | 56 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 55 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 54 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 18 |
| Famotidine | Famotidine | 49 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 49 | 18 |
| Trueplus Pen Needle | Pen Needle, Diabetic | 49 | 12 |
| Trazodone Hcl | Trazodone Hcl | 48 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | suppressed |
| Invokana | Canagliflozin | 45 | suppressed |
| Januvia | Sitagliptin Phosphate | 44 | 11 |
| Spironolactone | Spironolactone | 42 | 11 |
| Ezetimibe | Ezetimibe | 41 | suppressed |
| Finasteride | Finasteride | 41 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 14 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 38 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Eliquis | Apixaban | 29 | 11 |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Rexulti | Brexpiprazole | 28 | suppressed |
| Allopurinol | Allopurinol | 27 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 27 | 11 |
| Ibuprofen | Ibuprofen | 26 | 11 |
| Latanoprost | Latanoprost | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 25 | suppressed |
| Lidocaine | Lidocaine | 25 | suppressed |
| Testosterone | Testosterone | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Prednisone | Prednisone | 24 | 12 |
| Rybelsus | Semaglutide | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Simvastatin | Simvastatin | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Nisoldipine | Nisoldipine | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Probenecid | Probenecid | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $317.07 · 19 records | Gilead Sciences, Inc. | APRETUDE, Biktarvy, CABENUVA, DOVATO, JOBST SPORT, Yeztugo | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error